Phase 1 Data Support Further Investigation of RMC-6236 in KR

Kathryn C. Arbour, MD, discusses the unique mechanism of action of RMC-6236, the preliminary efficacy and safety findings for this agent in patients with KRAS-mutant NSCLC, and future directions for the RMC-6236-001 trial.

Related Keywords

Memorial Sloan Kettering Cancer Center , New York , United States , , Kathrync Arbour , D , Rmc 6236 , Patients With Kras Mutant Nsclc , Rmc 6236 001 Trial ,